Medical DirectorNordicRWE AS, Oslo, NorwayOppegård, Norway
Disclosure information not submitted.
Hypothetical target trial to compare the effectiveness of atezolizumab, pembrolizumab and nivolumab in second line treatment of advanced non-small cell lung cancer
Tuesday, August 27, 20242:15 PM – 2:30 PM CEST